We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-9.1%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$377M
AUM Growth
-$101M
Cap. Flow
-$18.7M
Cap. Flow %
-4.96%
Top 10 Hldgs %
50.73%
Holding
91
New
7
Increased
20
Reduced
15
Closed
11

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$5.15M
2
ALEC icon
Alector
ALEC
+$3.01M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$3M
4
KALV
KalVista Pharmaceuticals
KALV
+$2.61M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$2.49M

Top Sells

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$10.6M
2
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$10.4M
3
LMNX
Luminex Corp
LMNX
+$5.12M
4
PRQR icon
ProQR Therapeutics
PRQR
+$4.81M
5
TVRD
Tvardi Therapeutics
TVRD
+$4.5M

Sector Composition

Rank Sector Weight
1 Healthcare 91.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANNX icon
76
Annexon
ANNX
$918M
$434K 0.12%
+23,296
New +$473K
RDUS
77
DELISTED
Radius Health, Inc.
RDUS
$180K 0.05%
14,500
– –
NTBL
78
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$113K 0.03%
1,571
-7,200
-82% -$562K
ACRS icon
79
Aclaris Therapeutics
ACRS
$851M
– –
-100,000
Closed -$1.76M
APLS
80
DELISTED
Apellis Pharmaceuticals
APLS
– –
-12,703
Closed -$803K
ASND icon
81
Ascendis Pharma A/S
ASND
$16.4B
– –
-7,137
Closed -$939K
CNTB
82
Connect Biopharma Holdings
CNTB
$138M
– –
-8,000
Closed -$156K
RDHL
83
Redhill Biopharma
RDHL
$3.53M
– –
-456
Closed -$3.14M
SCPH
84
DELISTED
scPharmaceuticals
SCPH
– –
-38,891
Closed -$238K
TBPH icon
85
Theravance Biopharma
TBPH
$877M
– –
-732,345
Closed -$10.6M
TVRD
86
Tvardi Therapeutics
TVRD
$23.1M
– –
-8,750
Closed -$4.5M
CFMS
87
DELISTED
Conformis, Inc. Common Stock
CFMS
– –
-52,000
Closed -$1.5M
TBIO
88
DELISTED
Translate Bio, Inc. Common Stock
TBIO
– –
-376,993
Closed -$10.4M
LMNX
89
DELISTED
Luminex Corp
LMNX
– –
-139,091
Closed -$5.12M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, DAFNA Capital Management held 91 positions worth $377M, down 21% from $478M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DAFNA Capital Management withdrew a net $18.7M in Q3 2021, closing 11 positions and reducing 15 holdings. Its most notable exit was Theravance Biopharma, an estimated $10.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Cytokinetics worth $6.25M.

  • DAFNA Capital Management's largest Q3 2021 buy was Cytokinetics: 175,000 shares worth $6.25M.
  • DAFNA Capital Management added most to IDEAYA Biosciences in Q3 2021, an estimated $3M increase.
  • DAFNA Capital Management's biggest Q3 2021 reduction was ProQR Therapeutics, cutting an estimated $4.81M.
  • DAFNA Capital Management fully exited Theravance Biopharma in Q3 2021, selling an estimated $10.6M.
  • DAFNA Capital Management's ten largest holdings make up 51% of its $377M portfolio in Q3 2021.
  • DAFNA Capital Management opened 7 new positions and closed 11 in Q3 2021.
  • DAFNA Capital Management's portfolio value fell 21% quarter-over-quarter to $377M.

Based on DAFNA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.